268 related articles for article (PubMed ID: 32976576)
1. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease.
Curtis LM; Ostojic A; Venzon DJ; Holtzman NG; Pirsl F; Kuzmina ZJ; Baird K; Rose JJ; Cowen EW; Mays JW; Mitchell SA; Parsons-Wandell L; Joe GO; Comis LE; Berger A; Pusic I; Peer CJ; Figg WD; Cao L; Gale RP; Hakim FT; Pavletic SZ
Blood; 2021 Feb; 137(7):896-907. PubMed ID: 32976576
[TBL] [Abstract][Full Text] [Related]
2. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
3. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
DeFilipp Z; Li S; Kempner ME; Brown J; Del Rio C; Valles B; Hunnewell C; Saylor M; Vanderklish J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1836-1840. PubMed ID: 29758393
[TBL] [Abstract][Full Text] [Related]
4. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of pomalidomide given for patients with advanced solid tumors.
Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Miklos D; Cutler CS; Arora M; Waller EK; Jagasia M; Pusic I; Flowers ME; Logan AC; Nakamura R; Blazar BR; Li Y; Chang S; Lal I; Dubovsky J; James DF; Styles L; Jaglowski S
Blood; 2017 Nov; 130(21):2243-2250. PubMed ID: 28924018
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
11. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis.
Wertheimer T; Dohse M; Afram G; Weber D; Heidenreich M; Holler B; Kattner AS; Neubauer A; Mielke S; Ljungman P; Holler E; Herr W; Edinger M; Martínez AP; Fante M; Wolff D
Ann Hematol; 2021 Mar; 100(3):779-787. PubMed ID: 33515310
[TBL] [Abstract][Full Text] [Related]
12. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
13. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
Akpek G; Lee SM; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Li Y; Kassir N; Wang X; Palmisano M; Zhou S
J Clin Pharmacol; 2020 Aug; 60(8):1061-1075. PubMed ID: 32168381
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
Modi B; Hernandez-Henderson M; Yang D; Klein J; Dadwal S; Kopp E; Huelsman K; Mokhtari S; Ali H; Malki MMA; Spielberger R; Salhotra A; Zain J; Cotliar J; Parker P; Forman S; Nakamura R
Biol Blood Marrow Transplant; 2019 Feb; 25(2):265-269. PubMed ID: 30201397
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
17. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
Front Immunol; 2022; 13():954966. PubMed ID: 36189229
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
20. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
Jagasia M; Lazaryan A; Bachier CR; Salhotra A; Weisdorf DJ; Zoghi B; Essell J; Green L; Schueller O; Patel J; Zanin-Zhorov A; Weiss JM; Yang Z; Eiznhamer D; Aggarwal SK; Blazar BR; Lee SJ
J Clin Oncol; 2021 Jun; 39(17):1888-1898. PubMed ID: 33877856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
